TNG Transgene SA

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Strasbourg, January 7, 2025 – 06:00 pm CET

Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2024, the following resources were managed through the liquidity account:

  • 359,661 shares
  • € 80,653.30

In the second half of 2024, a total of:

Purchases 250,777 shares€ 243,947.381,154 market transactions
Sales229 905 shares€ 230,275.171,081 market transactions



It is recalled that when the liquidity program was initially established in 2016, the following resources were made available:

  • € 500,000.00



At the time the liquidity program was transferred to Natixis Oddo BHF SCA on January 2, 2020, the resources managed through the liquidity account consisted of:

  • 164,183 shares
  • € 246,158.00

Contacts

Transgene:



Lucie LARGUIER

CFO

+33 (0)3 88 27 91 00

 

Attachment



EN
07/01/2025

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
01/23/25 January 23, 2025 1 FR
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene to Participate in the Biomed Forum Investor Conference

Transgene to Participate in the Biomed Forum Investor Conference Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused on designing and develo...

January 21, 2025 1 EN
Christophe-Raphaël Ganet ... (+3)
  • Christophe-Raphaël Ganet
  • Oliver Metzger
  • Stephane Houri
AC ACCOR SA
TKA THYSSENKRUPP AG
ALESK ESKER SA
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
ADS ADIDAS AG
G1A GEA GROUP AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
TNG TRANSGENE SA
SZG SALZGITTER AG
LXS LANXESS AG
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
KCO KLOECKNER & CO SE
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
NOEJ NORMA GROUP SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
EVK EVONIK INDUSTRIES AG
MCPHY MCPHY ENERGY SA
BNR BRENNTAG SE
JUN3 JUNGHEINRICH AG PREF
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
DUE DURR AG
JST JOST WERKE AG
ALCUR ARCURE SA
HAG HENSOLDT AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
R3NK RENK GROUP AG
QGEN QIAGEN N.V.
01/15/25 January 15, 2025 1 FR
Christophe-Raphaël Ganet ... (+3)
  • Christophe-Raphaël Ganet
  • Oliver Metzger
  • Stephane Houri
AC ACCOR SA
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
ADS ADIDAS AG
G1A GEA GROUP AG
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
TNG TRANSGENE SA
SZG SALZGITTER AG
LXS LANXESS AG
ASY ASSYSTEM SA
GXI GERRESHEIMER AG
KCO KLOECKNER & CO SE
VOE VOESTALPINE AG
BOSS HUGO BOSS AG
ACX ACERINOX SA
NOEJ NORMA GROUP SE
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
NDA AURUBIS AG
FTON FEINTOOL INTERNATIONAL HOLDING AG
AALB AALBERTS N.V.
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
EVK EVONIK INDUSTRIES AG
MCPHY MCPHY ENERGY SA
BNR BRENNTAG SE
JUN3 JUNGHEINRICH AG PREF
RIO RIO TINTO PLC
SIE SIEMENS AG
BHP BHP GROUP LTD
DUE DURR AG
JST JOST WERKE AG
ALCUR ARCURE SA
HAG HENSOLDT AG
FPE3 FUCHS PETROLUB SE
DTG DAIMLER TRUCK
R3NK RENK GROUP AG
QGEN QIAGEN N.V.
01/15/25 January 15, 2025 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
TNG TRANSGENE SA

Transgene : Share price under pressure for no apparent reason

The recent clinical results of TG4050 and BT-001 strengthen the group's ambitions for both personalized vaccines and oncolytic viruses. TG4050 becomes, in our opinion, its main compound, to which two other candidates could be added: BT-001 and TG6050 with phase I results expected in 2025. Despite these positive clinical results, we are significantly adjusting our TP from € 2.2 to € 1.4 to factor in mainly: 1/ the current account advance of the major shareholder TSGH (Institut Mérieux Group), and...

01/14/25 January 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch